Shanghai yufang yixue (Sep 2022)

HIV-1 subtypes and pre-treatment drug resistance in newly reported HIV-1-infected cases in Hongkou District， Shanghai in 2016

  • HONG Liang,
  • TAO Jing,
  • LI Jiajie,
  • JIA Min

DOI
https://doi.org/10.19428/j.cnki.sjpm.2022.21665
Journal volume & issue
Vol. 34, no. 9
pp. 860 – 864

Abstract

Read online

ObjectiveTo determine the HIV-1 subtypes and pre-treatment drug resistance （PDR） mutations in newly reported HIV-1-infected cases in Hongkou District of Shanghai， and provide evidence for the adjustment of antiretroviral therapy （ART）.MethodsA total of 119 plasma samples of newly reported HIV-1-infected cases were collected in Hongkou District， Shanghai. Nucleic acid extraction was conducted to obtain HIV-1 RNA， and an in-house method was performed to amplify the pol gene fragment using reverse transcription PCR. The pol gene was then sequenced. Subtypes and PDR mutations were determined using HIV BLAST and HIV drug resistance online databases.ResultsA total of 89 HIV-1 pol gene fragments were obtained. Among them， CRF07_BC， CRF01_AE， B subtypes， CRF08_BC， CRF55_01B， and URF0107 accounted for 38.20%， 35.96%， 13.48%， 7.87%， 2.25%， and 2.25%， respectively. There were 13 samples with drug resistance mutations， of which 3 mutations were related to protease inhibitors （PIs）， 9 mutations were related to non-nucleoside reverse transcriptase inhibitors （NNRTIs）， and 1 mutation was related to nucleoside reverse transcriptase inhibitors （NRTIs）. Furthermore， 7 （7.87%， 7/89） PDR mutations were identified， of which 2 were highly resistant， 1 was intermediately resistant and 4 were lowly resistant. Additionally， 2 （2.25%， 2/89） PDR mutations belonged to the surveillance drug resistance mutations （SDRMs） list and surveillance of transmitted drug resistant （STDR）， with mutation sites being M184V and K103N， respectively， which were predicted to be highly resistant to efavirenz， nevirapine， emtricitabine， and lamivudine.ConclusionSurveillance on HIV-1 subtype and drug resistance should be strengthened， to focus on certain recombinant subtypes and PDR mutations， especially the URF0107 recombinant subtype and the transmitted drug resistance mutations related to efavirenz， nevirapine， emtricitabine， and lamivudine.

Keywords